RICHMOND, Texas, July 30 /PRNewswire/ -- DNA Heritage has recently overcome patent claims held by a competitor which would have severely restricted the use of DNA testing and databases that allow families around the world to match and connect up through their DNA. The patent covers the use of surnames and Y-chromosomes to establish a family connection. The UK Intellectual Property Office (UK IPO) has now rendered a formal opinion stating that the relevant claims are all invalid.

NEUHAUSEN AM RHEINFALL, Switzerland, July 30 /PRNewswire/ -- Aleris Rolled and Extruded Products Europe announced today the following price increases:

5% on all 2xxx and 7xxx plate products for aerospace applications

8% on conversion prices for coil coat applications

6% on conversion prices for all other rolled products regarding transactions denominated in Euros and 25% on conversion prices for all other rolled products regarding transactions denominated in United States Dollars

4% on all extruded products

VANCOUVER, Canada, July 30 /PRNewswire/ --

- But New Study Provides Hope in the Quest to Help Dogs Live Longer

Recently released global research shows that over 50% of dog owners are unaware that their dog may be at risk of heart failure. Heart disease affects one in four dogs over seven years of age(1), yet the lack of knowledge about this serious, life-threatening condition calls for better education amongst dog owners on how to recognise the disease, and how to maintain their dogs' heart health.

LONDON, July 30 /PRNewswire/ -- The Disciplinary Committee of the Royal College of Veterinary Surgeons (RCVS) has found Mr Leslie Higgott, of Wallasey, near Liverpool, guilty of Disgraceful Conduct in a Professional Respect and has directed that his name be removed from the Register of Veterinary Surgeons.

SAN MATEO, California, July 30 /PRNewswire/ --

- Evaluation Based on Completeness of Vision and Ability to Execute

MANHASSET, New York, July 30 /PRNewswire/ --

- Research, Best Practices and Expert Commentary to Help Businesses Succeed Amid Rapid Change

TechWeb, a division of United Business Media LLC, in conjunction with Satyam, Computer Services, Ltd. (NYSE: SAY), a leading global consulting and information technology services provider, launched TransformationEnablers.com, a new source of research, insights and expert commentary on how businesses can apply technology to transform their processes, practices and technologies for strategic advantage.

LONDON, July 30 /PRNewswire/ --

- Justoffbase Marks Fourth Successful Year Running Entire Estore with NetSuite Ecommerce

NEW YORK, July 30 /PRNewswire/ --

- With Photo

- Benefit T-Shirt Design By Karl Lagerfeld

- A Women's Cancer Initiative in Partnership with the Entertainment Industry Foundation's Women's Cancer Research Fund

Saks Fifth Avenue and the Entertainment Industry Foundation (EIF) announced today that Academy Award(R) winning actress Gwyneth Paltrow has been named the Entertainment Industry Foundation ambassador for Saks Fifth Avenue's 2008 KEY TO THE CURE campaign. KEY TO THE CURE is a women's cancer initiative founded in partnership with EIF's Women's Cancer Research Fund. The program will also receive ongoing support from Mercedes-Benz USA.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080730/NYW052)

MUMBAI, July 30 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for generic Depakote (R), divalproex sodium delayed release tablets.

Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches.

MARKHAM, Canada and OSAKA, Japan, July 30 /PRNewswire/ -- Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and commercialize CTA018, Cytochroma's novel vitamin D analog. CTA018 is entering Phase II development in Canada for the treatment of secondary hyperparathyroidism ("SHPT") in patients with chronic kidney disease ("CKD"). The agreement also grants MTPC access to certain follow-on compounds to CTA018 for the same territories, with Cytochroma retaining all rights to CTA018 and these follow-on compounds in all regions outside the U.S. and Asia.